Published in Vaccine Weekly, December 4th, 2002
D.A. Lewinsohn and colleagues at the Oregon Health & Science University, Portland VA Medical Center, conducted a study to see if "the potent CD4+ T-cell antigen Mtb39 is also a CD8+ T-cell antigen."
"A recombinant adenovirus-expressing Mtb39 (adenoMtb39) was used to infect monocyte-derived dendritic cells. Using interferon-gamma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.